AYLA Traded Higher On Unusual Volume. On July 25, Ayala filed a request to withdraw its S-1 Registration statement for the public offering it filed on July 18. The stock closed at $0.87 per share, then traded as high as $2.42 per share (up 178%) before closing at $1.69 per share on July 26. Daily volume was 101.6 million, compared with its 3-month average volume of 78.5 thousand shares per day.Part B of The RINGSIDE Trial Could Be Driving The Stock. The Phase 2/3 RINGSIDE trial is a two-part trial testing AL102, Ayala's gamma secretase inhibitor that blocks activation of the NOTCH signaling pathway. Tumors with mutations in the NOTCH pathway are associated with a more aggressive course of disease and poor outcomes. RINGSIDE is testing AL102 in desmoid tumors, a rare cancer of the connective tissue. Read More >>